Enrolment complete for phase-3 clinical trials of the new Covid-19 vaccine, Covishield in India.

Serum Institute of India (SII) in partnership with ICMR has enrolled around 1,600 participants and will conduct the trial across 15 different centers in India.

SII & ICMR have also collaborated for the clinical development of Covovax, a Covid-19 vaccine being developed by the US drug company, Novavax.

Next post